Researchers at Hebrew University of Jerusalem have published findings suggesting that compounds found in cannabis may offer a new therapeutic approach for treating a chronic liver disorder that affects approximately one-third of adults globally.

The study identifies cannabis compounds as potentially providing what researchers describe as a "new roadmap" for addressing what they characterize as the world's most common chronic liver condition. The research was conducted at the Hebrew University of Jerusalem, though specific details about the study methodology, sample size, or timeline were not provided in the initial reporting.

Chronic liver disorders represent a significant global health burden, with various conditions falling under this category including non-alcoholic fatty liver disease, which has become increasingly prevalent in developed nations. The research suggests that certain compounds within cannabis plants may have therapeutic properties that could be beneficial for liver health.

The findings come as medical research into cannabis compounds has expanded in recent years, with scientists investigating potential applications beyond the plant's psychoactive properties. However, the study's specific findings, including which cannabis compounds showed promise and the mechanism by which they might benefit liver health, have not been detailed in the preliminary reports.

Further research and clinical trials would typically be required before any potential treatments could be developed or approved for medical use. The study represents preliminary research in an ongoing field of investigation into the medical applications of cannabis-derived compounds.